
Michela Mc Casanova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7357134/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Trabectedin-irinotecan, a potentially promising combination in relapsed desmoplastic small round cell tumor: report of two cases. Journal of Chemotherapy, 2023, 35, 163-167.	1.5	8
2	Multiagent chemotherapy including IrIVA regimen and maintenance therapy in the treatment of desmoplastic small round cell tumor. Tumori, 2022, 108, 93-97.	1.1	9
3	Reply to H. B et al. Journal of Clinical Oncology, 2022, , JCO2102612.	1.6	1
4	Like apples, rhabdomyosarcomas come in so many kinds. Pediatric Blood and Cancer, 2022, 69, e29667.	1.5	1
5	Extraosseous Ewing sarcoma in children and adolescents: A retrospective series from a referral pediatric oncology center. Pediatric Blood and Cancer, 2022, 69, e29512.	1.5	3
6	Managing Care during the COVID-19 Pandemic: The Point of View and Fears of Pediatric Cancer Patients' Families. Children, 2022, 9, 554.	1.5	0
7	Longâ€term results from the multicentric European randomized phase 3 trial CWS/RMSâ€96 for localized highâ€risk soft tissue sarcoma in children, adolescents, and young adults. Pediatric Blood and Cancer, 2022, 69, e29691.	1.5	11
8	Adult-type non-rhabdomyosarcoma soft tissue sarcomas in pediatric age: Salvage rates and prognostic factors after relapse. European Journal of Cancer, 2022, 169, 179-187.	2.8	6
9	Metastatic Rhabdomyosarcoma: Results of the European <i>Paediatric</i> Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study. Journal of Clinical Oncology, 2022, 40, 3730-3740.	1.6	22
10	Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study. The Lancet Child and Adolescent Health, 2022, 6, 545-554.	5.6	11
11	Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas. European Journal of Cancer, 2022, 173, 71-90.	2.8	9
12	Impact of Rhabdomyosarcoma Treatment Modalities by Age in a Population-Based Setting. Journal of Adolescent and Young Adult Oncology, 2021, 10, 309-315.	1.3	7
13	Where are adolescents with cutaneous melanoma treated? An Italian nationwide study on referrals based on hospital discharge records. Pediatric Blood and Cancer, 2021, 68, e28566.	1.5	2
14	Experiencing Social Isolation (Even in the Era of COVID-19 Pandemic Lockdown): Teachings Through Arts from Adolescents with Cancer. Journal of Adolescent and Young Adult Oncology, 2021, 10, 346-350.	1.3	7
15	Adolescents with cancer on privacy: Fact-finding survey on the need for confidentiality and space. Tumori, 2021, 107, 452-457.	1.1	5
16	Looking out to see within: A photography project developed by adolescents with cancer during the COVID pandemic. Pediatric Blood and Cancer, 2021, 68, e28948.	1.5	5
17	Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis. British Journal of Cancer, 2021, 124, 1637-1646.	6.4	12
18	Integrating irinotecan in standard chemotherapy: A novel doseâ€density combination for highâ€risk pediatric sarcomas. Pediatric Blood and Cancer, 2021, 68, e28951.	1.5	10

#	Article	IF	CITATIONS
19	Complexity index in sarcoma and genomic grade index gene signatures in rhabdomyosarcoma of pediatric and adult ages. Pediatric Blood and Cancer, 2021, 68, e28987.	1.5	7
20	Nasopharyngeal carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatric Blood and Cancer, 2021, 68, e29018.	1.5	11
21	Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy. Tumori, 2021, 107, 276-281.	1.1	6
22	Correlation between oncological family history and clinical outcome in a large monocentric cohort of pediatric patients with rhabdomyosarcoma. International Journal of Clinical Oncology, 2021, 26, 1561-1568.	2.2	0
23	The Impact of Radiation Therapy in Children and Adolescents With Metastatic Rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2021, 111, 968-978.	0.8	15
24	Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Current Problems in Cancer, 2021, 45, 100768.	2.0	36
25	Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG). The Lancet Child and Adolescent Health, 2021, 5, 546-558.	5.6	28
26	Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial. Journal of Clinical Oncology, 2021, 39, 2979-2990.	1.6	38
27	Children and adolescent solid tumours and high-intensity end-of-life care: what can be done to reduce acute care admissions?. BMJ Supportive and Palliative Care, 2021, , bmjspcare-2021-003031.	1.6	0
28	Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Lancet Oncology, The, 2021, 22, 1312-1321.	10.7	50
29	Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. European Journal of Cancer, 2021, 157, 198-213.	2.8	34
30	"Based on a true story―podcast: a journey into the world of young patients with cancer. Tumori, 2021, , 030089162110626.	1.1	6
31	Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study. Pediatric Blood and Cancer, 2020, 67, e28032.	1.5	17
32	Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 cases. Modern Pathology, 2020, 33, 576-590.	5.5	36
33	Where Are Adolescents with Soft Tissue Sarcomas Treated? An Italian Nationwide Study on Referrals Based on Hospital Discharge Records. Journal of Adolescent and Young Adult Oncology, 2020, 9, 190-195.	1.3	7
34	A home run for rhabdomyosarcoma after 30 years: What now?. Tumori, 2020, 106, 5-11.	1.1	8
35	Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study. Lancet Oncology, The, 2020, 21, 134-144.	10.7	103
36	Secreting Germ Cell Tumors of the Central Nervous System: A Long-Term Follow-up Experience. Cancers, 2020, 12, 2688.	3.7	4

#	Article	IF	CITATIONS
37	A collateral effect of the COVIDâ€19 pandemic: Delayed diagnosis in pediatric solid tumors. Pediatric Blood and Cancer, 2020, 67, e28640.	1.5	43
38	Adolescents with Terminal Cancer: Making Good Use of Illusions. Journal of Adolescent and Young Adult Oncology, 2020, 9, 683-686.	1.3	1
39	Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies. European Journal of Cancer, 2020, 137, 183-192.	2.8	28
40	Defining the impact of prognostic factors at the time of relapse for nonmetastatic rhabdomyosarcoma. Pediatric Blood and Cancer, 2020, 67, e28674.	1.5	7
41	VIVA (vinorelbine, ifosfamide, vincristine, actinomycinâ€D): A new regimen in the armamentarium of systemic therapy for highâ€risk rhabdomyosarcoma. Pediatric Blood and Cancer, 2020, 67, e28649.	1.5	2
42	Pediatric Rhabdomyosarcomas: Three-Dimensional Radiological Assessments after Induction Chemotherapy Predict Survival Better than One-Dimensional and Two-Dimensional Measurements. Cancers, 2020, 12, 3808.	3.7	9
43	SARSâ€CoVâ€2 disease and children under treatment for cancer. Pediatric Blood and Cancer, 2020, 67, e28346.	1.5	19
44	Tumorial: Video Tutorials Produced by Young Patients on the Youth Project to Voice Their Experiences. Journal of Adolescent and Young Adult Oncology, 2020, 9, 436-440.	1.3	9
45	Precocious pseudopuberty, a paraneoplastic manifestation: a report of 2 cases. Tumori, 2020, 106, NP14-NP17.	1.1	3
46	Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. European Journal of Cancer, 2020, 135, 89-97.	2.8	13
47	Dermatofibrosarcoma protuberans in children and adolescents: The European Paediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Pediatric Blood and Cancer, 2020, 67, e28351.	1.5	11
48	Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients. Journal of Neuro-Oncology, 2020, 148, 619-628.	2.9	8
49	Cancer treatment in disabled children. European Journal of Pediatrics, 2020, 179, 1353-1360.	2.7	3
50	How young patients with cancer perceive the COVIDâ€19 (coronavirus) epidemic in Milan, Italy: Is there room for other fears?. Pediatric Blood and Cancer, 2020, 67, e28318.	1.5	81
51	The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. Oncologist, 2020, 25, e1777-e1784.	3.7	27
52	Investigating sexuality in adolescents with cancer: patients talk of their experiences. Pediatric Hematology and Oncology, 2020, 37, 223-234.	0.8	12
53	Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG). European Journal of Cancer, 2020, 127, 123-129.	2.8	71
54	Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy. European Journal of Cancer, 2020, 130, 72-80.	2.8	18

#	Article	IF	CITATIONS
55	YOUTH: the sweatshirt collection created by adolescents with cancer. Lancet Oncology, The, 2020, 21, 341-342.	10.7	12
56	Children with cancer in the time of COVIDâ€19: An 8â€week report from the six pediatric oncoâ€hematology centers in Lombardia, Italy. Pediatric Blood and Cancer, 2020, 67, e28410.	1.5	82
57	Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK) Journal of Clinical Oncology, 2020, 38, 10505-10505.	1.6	11
58	"What shall I do when I grow up?―Adolescents with cancer on the Youth Project in Milan play with their imagination and photography. Tumori, 2019, 105, 193-198.	1.1	11
59	Topotecan/carboplatin regimen for refractory/recurrent rhabdomyosarcoma in children: Report from the AIEOP Soft Tissue Sarcoma Committee. Tumori, 2019, 105, 138-143.	1.1	9
60	Comments on: The social phenomenon of "Christmas Balls,―the song of the adolescent patients of the Youth Project. Tumori, 2019, 105, 441-442.	1.1	0
61	Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTSâ€2005 prospective study. Pediatric Blood and Cancer, 2019, 66, e27833.	1.5	40
62	Age-Related Alterations in Immune Contexture Are Associated with Aggressiveness in Rhabdomyosarcoma. Cancers, 2019, 11, 1380.	3.7	15
63	Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 1566-1575.	10.7	161
64	"Summer is you― Adolescents and young adults with cancer sing about their desire for summer. Pediatric Blood and Cancer, 2019, 66, e27630.	1.5	12
65	Loop: there's no going back: A Graphic Novel by Adolescent Cancer Patients on the Youth Project in Milan. Journal of Medical Humanities, 2019, 40, 505-511.	0.7	8
66	Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single-center series. Medical Oncology, 2019, 36, 59.	2.5	24
67	Standard treatment and emerging drugs for managing synovial sarcoma: adult's and pediatric oncologist perspective. Expert Opinion on Emerging Drugs, 2019, 24, 43-53.	2.4	9
68	TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening. Journal of Clinical Oncology, 2019, 37, 513-524.	1.6	79
69	MiRNAs as Players in Rhabdomyosarcoma Development. International Journal of Molecular Sciences, 2019, 20, 5818.	4.1	15
70	A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas. Frontiers in Oncology, 2019, 9, 1271.	2.8	12
71	Evidence of hydroxyurea activity in children with pretreated desmoidâ€ŧype fibromatosis: A new option in the armamentarium of systemic therapies. Pediatric Blood and Cancer, 2019, 66, e27472.	1.5	14
72	Abstract CT081: Pediatric precision medicine program in recurrent tumors: Results of the first 500 patients included in the European MAPPYACTS molecular profiling trial. Cancer Research, 2019, 79, CT081-CT081.	0.9	3

#	Article	IF	CITATIONS
73	Randomized phase 2 trial of the combination of vincristine and irinotecan with or without temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS) Journal of Clinical Oncology, 2019, 37, 10000-10000.	1.6	16
74	Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients Journal of Clinical Oncology, 2019, 37, 10010-10010.	1.6	14
75	Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience Journal of Clinical Oncology, 2019, 37, 10018-10018.	1.6	3
76	Activity of chemotherapy in inflammatory myofibroblastic tumor (IMT): A retrospective analysis within the Italian Rare Tumours Network (RTR) Journal of Clinical Oncology, 2019, 37, e22545-e22545.	1.6	3
77	A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with <i>RET</i> -altered cancers Journal of Clinical Oncology, 2019, 37, TPS10066-TPS10066.	1.6	2
78	BRIMâ€P: A phase I, openâ€label, multicenter, doseâ€escalation study of vemurafenib in pediatric patients with surgically incurable, <i>BRAF</i> mutationâ€positive melanoma. Pediatric Blood and Cancer, 2018, 65, e26947.	1.5	29
79	The challenge of the management of adolescents and young adults with soft tissue sarcomas. Pediatric Blood and Cancer, 2018, 65, e27013.	1.5	24
80	Alveolar soft part sarcoma in children and adolescents: The European Paediatric Soft Tissue Sarcoma study group prospective trial (EpSSG NRSTS 2005). Pediatric Blood and Cancer, 2018, 65, e26942.	1.5	21
81	Targeting NTRK fusions for the treatment of congenital mesoblastic nephroma. Pediatric Blood and Cancer, 2018, 65, e26593.	1.5	8
82	Hepatoblastoma in children aged less than six months at diagnosis: A report from the SIOPEL group. Pediatric Blood and Cancer, 2018, 65, e26791.	1.5	16
83	Salvage rates and prognostic factors after relapse in children and adolescents with malignant peripheral nerve sheath tumors. Pediatric Blood and Cancer, 2018, 65, e26816.	1.5	14
84	Outcome of children and adolescents with central nervous system tumors in phase I trials. Journal of Neuro-Oncology, 2018, 137, 83-92.	2.9	2
85	Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. European Journal of Cancer, 2018, 100, 27-34.	2.8	22
86	PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study. BMC Cancer, 2018, 18, 652.	2.6	13
87	Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to â‰25 years with relapsed/refractory osteosarcoma (OS) Journal of Clinical Oncology, 2018, 36, 11527-11527.	1.6	22
88	Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) Journal of Clinical Oncology, 2018, 36, LBA2-LBA2.	1.6	23
89	Immunohistochemical and molecular profile of salivary gland cancer in children. Pediatric Blood and Cancer, 2017, 64, e26468.	1.5	14
90	Pediatric nonrhabdomyosarcoma soft tissue sarcomas arising at visceral sites. Pediatric Blood and Cancer, 2017, 64, e26490.	1.5	6

#	Article	IF	CITATIONS
91	The challenge of very rare childhood cancers in developed and developing countries. Expert Opinion on Orphan Drugs, 2017, 5, 331-341.	0.8	12
92	Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective. Nature Reviews Clinical Oncology, 2017, 14, 497-507.	27.6	61
93	Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro-Oncology, 2017, 19, 1542-1552.	1.2	130
94	Frontâ€line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group. Pediatric Blood and Cancer, 2017, 64, e26650.	1.5	1
95	Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2. Medical Oncology, 2017, 34, 191.	2.5	33
96	Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). European Journal of Cancer, 2017, 83, 177-184.	2.8	70
97	The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children: an international prospective case series. The Lancet Child and Adolescent Health, 2017, 1, 284-292.	5.6	43
98	From class waivers to precision medicine in paediatric oncology. Lancet Oncology, The, 2017, 18, e394-e404.	10.7	45
99	Winners' Cup: A National Football Tournament Brings Together Adolescent Patients with Cancer from all over Italy. Tumori, 2017, 103, e25-e29.	1.1	3
100	Response to Pazopanib in Two Pediatric Patients with Pretreated Relapsing Synovial Sarcoma. Tumori, 2017, 103, e1-e3.	1.1	12
101	"Christmas Ballsâ€+A Christmas Carol by the Adolescent Cancer Patients of the Milan Youth Project. Tumori, 2017, 103, e9-e14.	1.1	31
102	Searching for Happiness. Journal of Clinical Oncology, 2017, 35, 2209-2212.	1.6	28
103	Patient-derived xenografts, a multi-faceted in vivo model enlightening research on rare liver cancer biology. Hepatobiliary Surgery and Nutrition, 2017, 6, 344-346.	1.5	7
104	A phase I/II study of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumors (iMATRIX-Atezolizumab) Journal of Clinical Oncology, 2017, 35, 10524-10524.	1.6	9
105	Role of radiotherapy to primary/metastatic sites in pediatric patients with metastatic rhabdomyosarcoma in the BERNIE study Journal of Clinical Oncology, 2017, 35, 10541-10541.	1.6	3
106	Phase 1/2 study of the selective TRK inhibitor larotrectinib in pediatric patients with cancer Journal of Clinical Oncology, 2017, 35, TPS10577-TPS10577.	1.6	1
107	Non-Rhabdomyosarcoma Soft Tissue Sarcomas. , 2017, , 3121-3129.		0
108	Single-agent dose-finding cohort of a phase 1/2 study of lenvatinib (LEN) in children and adolescents with refractory or relapsed solid tumors Journal of Clinical Oncology, 2017, 35, 10544-10544.	1.6	1

#	Article	IF	CITATIONS
109	HG-06RE-IRRADIATION (RE-RT) FOR CHILDREN WITH RELAPSING DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): BETTER SURVIVAL AND BETTER TIME. Neuro-Oncology, 2016, 18, iii49.1-iii49.	1.2	0
110	Oral Etoposide in Relapsed or Refractory Ewing Sarcoma: A Monoinstitutional Experience in Children and Adolescents. Tumori, 2016, 102, 84-88.	1.1	6
111	Model of Care for Adolescents and Young Adults with Cancer: The Youth Project in Milan. Frontiers in Pediatrics, 2016, 4, 88.	1.9	19
112	EPT-07PARTICIPATION OF CHILDREN AND ADOLESCENTS WITH CENTRAL NERVOUS SYSTEM TUMOURS IN PHASE I TRIALS WITHIN THE ITCC EUROPEAN CONSORTIUM. Neuro-Oncology, 2016, 18, iii25.2-iii25.	1.2	1
113	Adolescents' Health Awareness and Understanding of Cancer and Tumor Prevention: When and Why an Adolescent Decides to Consult a Physician. Pediatric Blood and Cancer, 2016, 63, 1357-1361.	1.5	24
114	Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study—EpSSG NRSTS 2005. European Journal of Cancer, 2016, 60, 69-82.	2.8	63
115	Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study. European Journal of Cancer, 2016, 67, 130-140.	2.8	17
116	The Sooner the Better? How Symptom Interval Correlates With Outcome in Children and Adolescents With Solid Tumors: Regression Tree Analysis of the Findings of a Prospective Study. Pediatric Blood and Cancer, 2016, 63, 479-485.	1.5	45
117	MB-03LONG TERM FOLLOW-UP OF PATIENTS WITH METASTATIC (M+) AND OTHER HIGH-RISK MEDULLOBLASTOMA WITH TAILORED-DOSES HYPERFRACTIONATED ACCELERATED RADIOTHERAPY (HART) CRANIOSPINAL IRRADIATION (CSI) PLUS/MINUS HIGH-DOSE THIOTEPA. Neuro-Oncology, 2016, 18, iii97.3-iii97.	1.2	Ο
118	Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. British Journal of Clinical Pharmacology, 2016, 81, 148-160.	2.4	38
119	Measuring the efficacy of a project for adolescents and young adults with cancer: A study from the Milan Youth Project. Pediatric Blood and Cancer, 2016, 63, 2197-2204.	1.5	28
120	Hepatocellular Carcinoma in Children: Does Modified Platinum- and Doxorubicin-Based Chemotherapy Increase Tumor Resectability and Change Outcome? Lessons Learned From the SIOPEL 2 and 3 Studies. Journal of Clinical Oncology, 2016, 34, 1050-1056.	1.6	69
121	Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study GroupÂexperience. European Journal of Cancer, 2016, 57, 1-9.	2.8	94
122	International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents. Cancer Chemotherapy and Pharmacology, 2016, 77, 289-298.	2.3	57
123	Phase 1/2 study of weekly <i>nab</i> -paclitaxel (<i>nab</i> -P) in pediatric patients (pts) with recurrent/refractory solid tumors (STs): Dose-finding and pharmacokinetics (PK) Journal of Clinical Oncology, 2016, 34, 10551-10551.	1.6	4
124	BERNIE: Open-label, randomized, phase II study of bevacizumab plus chemotherapy in pediatric metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) Journal of Clinical Oncology, 2016, 34, 11054-11054.	1.6	2
125	Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma. Oncotarget, 2016, 7, 58903-58914.	1.8	15
126	Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes. ELife, 2016, 5, .	6.0	5

#	Article	IF	CITATIONS
127	Creating Beauty: The Experience of a Fashion Collection Prepared by Adolescent Patients at a Pediatric Oncology Unit. Tumori, 2015, 101, 626-630.	1.1	33
128	New strategies to ensure good patient–physician communication when treating adolescents and young adults with cancer: the proposed model of the Milan Youth Project. Clinical Oncology in Adolescents and Young Adults, 2015, , 63.	0.8	0
129	Considering chemotherapy in synovial sarcoma. Expert Opinion on Orphan Drugs, 2015, 3, 1111-1124.	0.8	4
130	Clouds of Oxygen: Adolescents With Cancer Tell Their Story in Music. Journal of Clinical Oncology, 2015, 33, 218-221.	1.6	47
131	A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma. Clinical Cancer Research, 2015, 21, 585-593.	7.0	50
132	Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Annals of Oncology, 2015, 26, 567-572.	1.2	115
133	Salivary gland carcinomas in children and adolescents: The Italian TREP project experience. Pediatric Blood and Cancer, 2014, 61, 1961-1968.	1.5	35
134	Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. European Journal of Cancer, 2014, 50, 170-177.	2.8	47
135	Axial skeletal osteosarcoma: a 25-year monoinstitutional experience in children and adolescents. Medical Oncology, 2014, 31, 875.	2.5	17
136	Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. Journal of Neuro-Oncology, 2014, 118, 305-312.	2.9	61
137	Thyroid carcinoma after treatment for malignancies in childhood and adolescence: from diagnosis through follow-up. Medical Oncology, 2014, 31, 121.	2.5	11
138	Non-rhabdomyosarcoma Soft Tissue Sarcomas. , 2014, , 1-10.		0
139	Results of nimotuzumab and vinorelbine, radiation, and re-irradiation for diffuse pontine glioma in childhood Journal of Clinical Oncology, 2014, 32, 10020-10020.	1.6	1
140	Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncology, The, 2013, 14, 834-842.	10.7	251
141	Fibroblastic tumors of intermediate malignancy in childhood. Expert Review of Anticancer Therapy, 2013, 13, 225-236.	2.4	16
142	Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience. Child's Nervous System, 2013, 29, 1107-1112.	1.1	14
143	Relapses in hepatoblastoma patients: Clinical characteristics and outcome – Experience of the International Childhood Liver Tumour Strategy Group (SIOPEL). European Journal of Cancer, 2013, 49, 915-922.	2.8	87
144	Paediatric and adolescent alveolar soft part sarcoma: A joint series from European cooperative groups. Pediatric Blood and Cancer, 2013, 60, 1826-1832.	1.5	59

#	Article	IF	CITATIONS
145	Relapse in synovial sarcoma: what can be done for poor outcomes?. Clinical Practice (London,) Tj ETQq1 1 0	.784314 rgBT	/Oyerlock 10
146	Neonatal soft tissue sarcomas. Seminars in Fetal and Neonatal Medicine, 2012, 17, 231-238.	2.3	61
147	Synovial sarcoma in children and adolescents: A critical reappraisal of staging investigations in relation to the rate of metastatic involvement at diagnosis. European Journal of Cancer, 2012, 48, 1370-1375.	2.8	25
148	Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma. European Journal of Cancer, 2012, 48, 3448-3455.	2.8	41
149	Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma – A phase II trial of the childhood liver tumour strategy group (SIOPEL). European Journal of Cancer, 2012, 48, 3456-3464.	2.8	49
150	The challenge of access to care for soft tissue sarcomas bridging pediatric and adult age: the Italian pediatric oncology view. Expert Review of Anticancer Therapy, 2012, 12, 243-254.	2.4	16
151	The Youth Project at the Istituto Nazionale Tumori in Milan. Tumori, 2012, 98, 399-407.	1.1	58
152	Long-term results of combined preradiation chemotherapy and age-tailored radiotherapy doses for childhood medulloblastoma. Journal of Neuro-Oncology, 2012, 108, 163-171.	2.9	20
153	A prospective protocol for nasopharyngeal carcinoma in children and adolescents. Cancer, 2012, 118, 2718-2725.	4.1	87
154	A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors Journal of Clinical Oncology, 2012, 30, 9519-9519.	1.6	21
155	The Youth Project at the Istituto Nazionale Tumori in Milan. Tumori, 2012, 98, 399-407.	1.1	28
156	Liver Tumors. Pediatric Oncology, 2012, , 303-312.	0.5	0
157	Two Cases of Adolescents with Paratesticular Rhabdomyosarcoma Inadequately Treated: The Problem of Referral. Journal of Adolescent and Young Adult Oncology, 2011, 1, 152-154.	1.3	2
158	Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Translational Oncology, 2011, 4, 203-211.	3.7	35
159	Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: Results of a pooled analysis from United States and European groups. European Journal of Cancer, 2011, 47, 724-731.	2.8	123
160	Pharmacotherapy for pediatric soft-tissue sarcomas. Expert Opinion on Pharmacotherapy, 2011, 12, 517-531.	1.8	17
161	Soft tissue sarcoma across the age spectrum: A populationâ€based study from the surveillance epidemiology and end results database. Pediatric Blood and Cancer, 2011, 57, 943-949.	1.5	270
162	Cancer predisposition in children with Kabuki syndrome. American Journal of Medical Genetics, Part A, 2011, 155, 1504-1504.	1.2	17

#	Article	IF	CITATIONS
163	Salivary gland carcinomas in children and adolescents: A populationâ€based study, with comparison to adult cases. Head and Neck, 2011, 33, 1476-1481.	2.0	119
164	Non-Rhabdomyosarcoma Soft Tissue Sarcomas. , 2011, , 2539-2546.		0
165	Tumori in età pediatrica. , 2011, , 269-279.		0
166	Aggressive fibromatosis in children and adolescents. Cancer, 2010, 116, 233-240.	4.1	121
167	The symptom interval in children and adolescents with soft tissue sarcomas. Cancer, 2010, 116, 177-183.	4.1	66
168	A lower-dose, lower-toxicity cisplatin–etoposide regimen for childhood progressive low-grade glioma. Journal of Neuro-Oncology, 2010, 100, 65-71.	2.9	74
169	Distinct features of colorectal cancer in children and adolescents. Cancer, 2010, 116, 758-765.	4.1	126
170	End of life in children with cancer: Experience at the Pediatric Oncology Department of the Istituto Nazionale Tumori in Milan. Pediatric Blood and Cancer, 2010, 54, 88-91.	1.5	25
171	Inflammatory myofibroblastic tumor of the conjunctiva: Response to chemotherapy with lowâ€dose methotrexate and vinorelbine. Pediatric Blood and Cancer, 2010, 54, 483-485.	1.5	23
172	Differential features of nasopharyngeal carcinoma in children and adults: A SEER study. Pediatric Blood and Cancer, 2010, 55, 279-284.	1.5	99
173	Definition, outcome, and intracranial hemorrhage in childhood chronic ITP. Pediatric Blood and Cancer, 2010, 55, 587-587.	1.5	5
174	Prolonged 14â€day continuous infusion of highâ€dose ifosfamide with an external portable pump: Feasibility and efficacy in refractory pediatric sarcoma. Pediatric Blood and Cancer, 2010, 55, 617-620.	1.5	32
175	Objective response to hydroxyurea in a patient with heavily preâ€ŧreated aggressive fibromatosis. Pediatric Blood and Cancer, 2010, 55, 588-589.	1.5	13
176	Neuroblastoma in Patients over 12 Years Old: A 20-Year Experience at the Istituto Nazionale Tumori of Milan. Tumori, 2010, 96, 684-689.	1.1	23
177	Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma. Journal of Clinical Oncology, 2010, 28, 1322-1328.	1.6	58
178	Peculiar features and tailored management of adult cancers occurring in pediatric age. Expert Review of Anticancer Therapy, 2010, 10, 1837-1851.	2.4	27
179	Infantile Fibrosarcoma: Management Based on the European Experience. Journal of Clinical Oncology, 2010, 28, 318-323.	1.6	204
180	Soft tissue sarcomas in the first year of life. European Journal of Cancer, 2010, 46, 2449-2456.	2.8	57

#	Article	IF	CITATIONS
181	Soft Tissue Sarcomas of Childhood and Adolescence: The Prognostic Role of Tumor Size in Relation to Patient Body Size. Journal of Clinical Oncology, 2009, 27, 371-376.	1.6	55
182	RHABDOMYOSARCOMA OF THE EXTREMITIES: A Focus on Tumors Arising in the Hand and Foot. Pediatric Hematology and Oncology, 2009, 26, 321-331.	0.8	18
183	Prognostic role of tumor size in childhood cancer. Future Oncology, 2009, 5, 1605-1613.	2.4	4
184	Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005. Cancer, 2009, 115, 3537-3547.	4.1	260
185	Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma. Medical Oncology, 2009, 26, 67-72.	2.5	12
186	No Salvage Using High-Dose Chemotherapy Plus/Minus Reirradiation for Relapsing Previously Irradiated Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1358-1363.	0.8	44
187	Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. Journal of Neuro-Oncology, 2008, 87, 355-361.	2.9	59
188	Full-dose ifosfamide can be safely administered to outpatients. Pediatric Blood and Cancer, 2008, 50, 375-378.	1.5	14
189	The clinical significance of tumor grade in non-rhabdomyosarcoma soft tissue sarcomas. Pediatric Blood and Cancer, 2008, 50, 188-188.	1.5	1
190	Colorectal carcinoma in children and adolescents: The experience of the Istituto Nazionale Tumori of Milan, Italy. Pediatric Blood and Cancer, 2008, 50, 588-593.	1.5	88
191	Late relapse of embryonal rhabdomyosarcoma, botryoid variant, of the vagina. Pediatric Blood and Cancer, 2008, 51, 140-141.	1.5	5
192	Psychological referral and consultation for adolescents and young adults with cancer treated at pediatric oncology unit. Pediatric Blood and Cancer, 2008, 51, 105-109.	1.5	44
193	Treating Pediatric soft tissue sarcomas in a country with limited resources: The experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala. Pediatric Blood and Cancer, 2008, 51, 760-764.	1.5	20
194	Synovial sarcoma of children and adolescents: The prognostic role of axial sites. European Journal of Cancer, 2008, 44, 1202-1209.	2.8	81
195	Molecular Characterization of Synovial Sarcoma in Children and Adolescents: Evidence of Akt Activation. Translational Oncology, 2008, 1, 95-101.	3.7	31
196	A Case of Congenital Peripheral Primitive Neuroectodermal Tumor Presenting With Multiple Metastases. Journal of Pediatric Hematology/Oncology, 2008, 30, 36-38.	0.6	16
197	Angiomatoid Fibrous Histiocytoma in an HIV-positive Child. Journal of Pediatric Hematology/Oncology, 2008, 30, 242-244.	0.6	6
198	An Adolescent with Rhabdomyosarcoma during Pregnancy. Tumori, 2008, 94, 431-433.	1.1	10

#	Article	IF	CITATIONS
199	Psychological Assessment of Women on an Early Breast Screening Program after Radiotherapy to the Chest Wall for Childhood Cancer. Tumori, 2008, 94, 568-573.	1.1	6
200	Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing's family tumours. European Journal of Cancer, 2007, 43, 885-890.	2.8	7
201	Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma. European Journal of Cancer, 2007, 43, 2691-2697.	2.8	43
202	Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer, 2007, 109, 1406-1412.	4.1	109
203	Evidence for activation of KIT, PDGFRα, and PDGFRβ receptors in the Ewing sarcoma family of tumors. Cancer, 2007, 109, 1638-1645.	4.1	32
204	Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor. Pediatric Blood and Cancer, 2007, 49, 864-866.	1.5	36
205	Soft-tissue sarcomas of the extremities in patients of pediatric age. Journal of Children's Orthopaedics, 2007, 1, 195-203.	1.1	11
206	Soft-Tissue Sarcomas. , 2007, , 185-201.		0
207	Assistance to Parents who have Lost their Child with Cancer. Tumori, 2006, 92, 306-310.	1.1	6
208	Grossly-resected synovial sarcoma treated by the German and Italian Pediatric Soft Tissue Sarcoma Cooperative Groups: Discussion on the role of adjuvant therapies. Pediatric Blood and Cancer, 2006, 46, 11-17.	1.5	73
209	Salivary gland neoplasms in children: The experience of the Istituto Nazionale Tumori of Milan. Pediatric Blood and Cancer, 2006, 47, 806-810.	1.5	96
210	Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1031-1037.	0.8	47
211	A Case of Relapsing Glioblastoma Multiforme Responding to Vinorelbine. Journal of Neuro-Oncology, 2006, 80, 195-201.	2.9	14
212	Epithelioid sarcoma in children and adolescents. Cancer, 2006, 106, 708-717.	4.1	112
213	Rhabdomyosarcoma of the Head and Neck Region: Experience at the Pediatric Unit of the Istituto Nazionale Tumori, Milan. The Journal of Otolaryngology, 2006, 35, 53.	0.6	19
214	Specification on the Definition of Adult-Type Soft Tissue Sarcoma. Journal of Clinical Oncology, 2006, 24, 4042-4043.	1.6	10
215	Carcinoid Tumor of the Appendix in Childhood: The Experience of Two Italian Institutions. Journal of Pediatric Gastroenterology and Nutrition, 2005, 40, 216-219.	1.8	51
216	Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment. British Journal of Cancer, 2005, 92, 1984-1988.	6.4	11

#	Article	IF	CITATIONS
217	Evolving treatment strategies for parameningeal rhabdomyosarcoma: The experience of the istituto nazionale tumori of Milan. Head and Neck, 2005, 27, 49-57.	2.0	16
218	The IVADo regimen?A pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma. Cancer, 2005, 103, 1719-1724.	4.1	56
219	Localized unresectable non-rhabdo soft tissue sarcomas of the extremities in pediatric age. Cancer, 2005, 104, 2006-2012.	4.1	22
220	The role of adjuvant chemotherapy in children and adolescents with surgically resected, high-risk adult-type soft tissue sarcomas. Pediatric Blood and Cancer, 2005, 45, 128-134.	1.5	32
221	Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro-Oncology, 2005, 7, 41-48.	1.2	56
222	ETOPOSIDE, CISPLATIN, EPIRUBICIN CHEMOTHERAPY IN THE TREATMENT OF PEDIATRIC LIVER TUMORS. Pediatric Hematology and Oncology, 2005, 22, 189-198.	0.8	6
223	Adult-Type Soft Tissue Sarcomas in Pediatric-Age Patients: Experience at the Istituto Nazionale Tumori in Milan. Journal of Clinical Oncology, 2005, 23, 4021-4030.	1.6	130
224	Does Melanoma Behave Differently in Younger Children Than in Adults? A Retrospective Study of 33 Cases of Childhood Melanoma From a Single Institution. Pediatrics, 2005, 115, 649-654.	2.1	215
225	New concepts for the treatment of pediatric nonrhabdomyosarcoma soft tissue sarcomas. Expert Review of Anticancer Therapy, 2005, 5, 307-318.	2.4	68
226	Current chemotherapeutic strategies for rhabdomyosarcoma. Expert Review of Anticancer Therapy, 2005, 5, 283-294.	2.4	35
227	Pediatric Malignant Peripheral Nerve Sheath Tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group. Journal of Clinical Oncology, 2005, 23, 8422-8430.	1.6	308
228	Clinical Experience with Psychological Aspects in Pediatric Patients Amputated for Malignancies. Tumori, 2004, 90, 399-404.	1.1	8
229	CUTANEOUS ANGIOSARCOMA IN A PATIENT WITH XERODERMA PIGMENTOSUM. Pediatric Hematology and Oncology, 2004, 21, 23-26.	0.8	22
230	What chemotherapy should alveolar paratesticular rhabdomyosarcoma receive?. Pediatric Blood and Cancer, 2004, 43, 295-295.	1.5	2
231	Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution. Cancer, 2004, 101, 627-634.	4.1	345
232	Adult Wilms' tumor: A monoinstitutional experience and a review of the literature. Cancer, 2004, 101, 289-293.	4.1	77
233	Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas. Cancer, 2004, 101, 1664-1671.	4.1	113
234	FIVE QUESTIONS FOR ASSESSING PSYCHOLOGICAL PROBLEMS IN PEDIATRIC PATIENTS CURED OF NEOPLASTIC DISEASE. Pediatric Hematology and Oncology, 2004, 21, 481-487.	0.8	9

#	Article	IF	CITATIONS
235	Cutaneous Angiosarcoma in a Patient with Xeroderma Pigmentosum. Pediatric Hematology and Oncology, 2004, 21, 23-26.	0.8	11
236	Role of surgery for nonmetastatic abdominal rhabdomyosarcomas. Cancer, 2003, 97, 1974-1980.	4.1	38
237	Rhabdomyosarcoma in infants younger than one year old. Cancer, 2003, 97, 2597-2604.	4.1	82
238	Rhabdomyosarcoma in adults. Cancer, 2003, 98, 571-580.	4.1	360
239	Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children. Medical and Pediatric Oncology, 2003, 41, 74-76.	1.0	35
240	Synovial Sarcoma of Childhood and Adolescence: A Multicenter, Multivariate Analysis of Outcome. Journal of Clinical Oncology, 2003, 21, 1602-1611.	1.6	217
241	Immunomodulation in a Treatment Program Including Pre- and Post-Operative Interleukin-2 and Chemotherapy for Childhood Osteosarcoma. Tumori, 2003, 89, 263-268.	1.1	29
242	Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori, 2003, 89, 263-8.	1.1	14
243	Intensive, Very Short-Term Chemotherapy for Advanced Burkitt's Lymphoma in Children. Journal of Clinical Oncology, 2002, 20, 2783-2788.	1.6	47
244	Paratesticular Rhabdomyosarcoma: Report From the Italian and German Cooperative Group. Journal of Clinical Oncology, 2002, 20, 449-455.	1.6	72
245	High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma. Journal of Clinical Oncology, 2002, 20, 4209-4216.	1.6	171
246	Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis in Childhood and Adolescence: An Analysis of 31 Cases. Journal of Pediatric Hematology/Oncology, 2002, 24, 454-458.	0.6	14
247	Response to chemotherapy in a child with primary bronchopulmonary leiomyosarcoma. Medical and Pediatric Oncology, 2002, 39, 55-57.	1.0	14
248	Psychological support in children and adolescents with cancer when amputation is required. Medical and Pediatric Oncology, 2002, 38, 261-265.	1.0	3
249	Malignant vascular tumors in children and adolescents: A report from the Italian and German soft tissue sarcoma cooperative group. Medical and Pediatric Oncology, 2002, 39, 109-114.	1.0	85
250	Clear cell sarcoma of tendons and aponeuroses in pediatric patients. Cancer, 2002, 94, 3269-3276.	4.1	96
251	Vinorelbine in previously treated advanced childhood sarcomas. Cancer, 2002, 94, 3263-3268.	4.1	73
252	Undifferentiated nasopharyngeal carcinoma in children and adolescents: Comparison between staging systems. Annals of Oncology, 2001, 12, 1157-1162.	1.2	11

#	Article	IF	CITATIONS
253	Childhood leiomyosarcoma: A report from the Soft Tissue Sarcoma Italian Cooperative Group. Annals of Oncology, 2001, 12, 1163-1168.	1.2	28
254	Hemangiopericytoma in pediatric ages. Cancer, 2001, 92, 2692-2698.	4.1	52
255	Childhood Malignant Ovarian Germ Cell Tumors: A Monoinstitutional Experience. Gynecologic Oncology, 2001, 81, 436-440.	1.4	15
256	Concomitant chemoradiotherapy for childhood poor-prognosis gliomas. , 2000, 34, 147-150.		4
257	NASOPHARYNGEAL CARCINOMA IN A BOY WITH FRAGILE X SYNDROME. Pediatric Hematology and Oncology, 2000, 17, 597-600.	0.8	5
258	CHILDHOOD LIPOSARCOMA: A Single-Institutional Twenty-Year Experience. Pediatric Hematology and Oncology, 1999, 16, 415-421.	0.8	25
259	Synovial sarcoma: Report of a series of 25 consecutive children from a single institution. , 1999, 32, 32-37.		54
260	Malignant Peripheral Nerve Sheath Tumors in Children. Journal of Pediatric Hematology/Oncology, 1999, 21, 509-513.	0.6	49
261	THE MANAGEMENT OF PARATESTICULAR RHABDOMYOSARCOMA: A SINGLE INSTITUTIONAL EXPERIENCE WITH 44 CONSECUTIVE CHILDREN. Journal of Urology, 1998, 159, 1031-1034.	0.4	39
262	Neuron-Specific Enolase Evaluation in Patients with Neuroblastoma. Tumor Biology, 1998, 19, 261-268.	1.8	33
263	Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Annals of Oncology, 1997, 8, 247-250.	1.2	53
264	How ten-years of reirradiation for paediatric high-grade glioma may shed light on first line treatment. Journal of Neuro-Oncology, 0, , .	2.9	0
265	Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience. Pediatric Blood and Cancer, 0, , .	1.5	3